DAX23.163 -0,1%Est505.542 +0,1%MSCI World4.343 -0,1%Top 10 Crypto12,24 -4,4%Nas22.455 +0,1%Bitcoin77.164 -3,7%Euro1,1525 -0,5%Öl63,46 -2,1%Gold4.075 +0,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 DroneShield A2DMAA RENK RENK73 Siemens Energy ENER6Y Amazon 906866 Deutsche Telekom 555750 TKMS thyssenkrupp Marine Systems TKMS00 Lufthansa 823212 Siemens 723610 Alphabet A (ex Google) A14Y6F Plug Power A1JA81 Tesla A1CX3T SAP 716460 BASF BASF11
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Hochspannung vor NVIDIA-Zahlen -- Wall Street verhalten freundlich -- DAX beendet Handel stabil -- Mercedes-Benz, Siemens Energy, Rheinmetall, TKMS, DroneShield, Plug Power im Fokus
Top News
NVIDIA-Aktie vor den Quartalszahlen: Sollten Anleger noch zugreifen oder in Deckung gehen? NVIDIA-Aktie vor den Quartalszahlen: Sollten Anleger noch zugreifen oder in Deckung gehen?
Die Top-US-Aktien der UBS: Ein Blick in das Portfolio des Schweizer Finanzriesen Die Top-US-Aktien der UBS: Ein Blick in das Portfolio des Schweizer Finanzriesen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

AbbVie Aktie

Kaufen
Verkaufen
AbbVie Aktien-Sparplan
201,00 EUR -2,00 EUR -0,99 %
FSE
231,29 USD -2,58 USD -1,10 %
BTT
AbbVie jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.357,08 Mrd. EUR

KGV74,34Div. Rendite3,54%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1J84E

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00287Y1091

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolABBV

AbbVie Aktien News

DatumMeistgelesen
PR NewswireAbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
ZacksPre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?
ZacksAbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
MotleyFoolThe 3 Things That Matter for AbbVie Now
ZacksAbbVie (ABBV) Outperforms Broader Market: What You Need to Know
PR NewswireBOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project
ZacksAbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
ZacksAbbVie (ABBV) Surpasses Market Returns: Some Facts Worth Knowing
PR NewswireAbbVie's 10th 'Week of Possibilities' Unites Employees Across Asia for Community Impact
ZacksHere's How to Play AbbVie Stock as it Reaches Golden Cross
PR NewswireRefresh Releases First of its Kind Eye Drop for Dry Eyes
ZacksAbbVie (ABBV) Laps the Stock Market: Here's Why
BenzingaWhy Is AbbVie Stock Trading Higher On Thursday?
PR NewswireIchnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
PR NewswireAbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
ZacksAbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
ZacksIs It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?
ZacksThe Zacks Analyst Blog Highlights Alphabet, AbbVie and The Walt Disney
ZacksWhy AbbVie (ABBV) is a Top Value Stock for the Long-Term
ZacksTop Stock Reports for Alphabet, AbbVie & Walt Disney
PR NewswireAbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology
PR NewswireU.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
PR NewswireAbbVie to Host Second-Quarter 2025 Earnings Conference Call
ZacksAbbVie (ABBV) Stock Dips While Market Gains: Key Facts
ZacksAbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock
ZacksHere's Why AbbVie (ABBV) is a Strong Momentum Stock
ZacksInvestors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
PR NewswireAbbVie Declares Quarterly Dividend
PR NewswireAbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention
ZacksHere's Why AbbVie (ABBV) Fell More Than Broader Market
ZacksIs AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?
ZacksHere's Why AbbVie (ABBV) is a Strong Value Stock
PR NewswireAbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
ZacksAbbVie (ABBV) Gains As Market Dips: What You Should Know
PR NewswireU.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus
ZacksHere is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
BenzingaRecent Filing Shows That Rep. Robert Bresnahan Bought Over $28K Worth of AbbVie Stock
ZacksHave Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?
ZacksAbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know
PR NewswireAbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals

AbbVie News

AbbVie News: auf dieser Seite finden Sie alle AbbVie News und Nachrichten zur AbbVie Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch AbbVie News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um AbbVie News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.